Penumbra opened lower at $320.56, compared with its previous close of $321.97. In the last trading session, the stock traded between $319.66 and $321.83. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Penumbra is now worth
$ 115.63
giving a profit of
$ 15.63 (15.63%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-2.19 (-0.68%)
Day High
$321.83
Day Low
$319.66
Day Open
$320.56
Prev Close
$321.97
Volume
1,76,097
1W Return
-1.63%
1M Return
0.30%
3M Return
-0.10%
6M Return
-1.55%
1Y Return
37.03%
Market Cap ($ Mn)
12,596
PE Ratio
79.04
PB Ratio
8.28
PEG Ratio
1.37
ROE
13.79%
ROCE
12.60%
EPS (TTM)
$0.88
1 Week
-1.63%
1 Month
0.30%
3 Months
-0.10%
6 Months
-1.55%
9 Months
-10.43%
Penumbra Q2 Results: EPS Misses Estimate, Revenue Rises 14.89% YoY
Penumbra's Q2 results show a split performance: revenue beat estimates at $390.046M, up 14.89% YoY, but EPS missed significantly at $0.88 versus the $1.20 estimate. The 23.48% drop in EPS from the prior year contrasts with robust sales growth, indicating margin pressure.
3mo agoPenumbra THUNDER study shows THUNDERBOLT is safe and effective
Penumbra, Inc. reported that the THUNDER study confirmed the safety and effectiveness of its THUNDERBOLT system for stroke care, achieving an 87.5% successful reperfusion rate. The study of 216 patients showed rapid revascularization times and low complication rates, supporting the device's recent U.S. FDA clearance and CE Mark.
3mo agoPenumbra initiates FORWARD trial for thrombectomy safety data
Penumbra, Inc. has initiated the FORWARD study, an international, multi-center trial to collect safety and efficacy data on mechanical thrombectomy for acute ischemic stroke with distal occlusions. The study includes computer assisted vacuum thrombectomy (CAVT™) and modulated aspiration. The first patient was treated by Dr. Keith Woodward at Vista Radiology in Knoxville, Tenn.
3mo agoEvercore ISI maintains Outperform on Penumbra, cuts target to $320
Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating on Penumbra (NYSE: PEN) but lowered the price target to $320 from $335. The revision reflects updated valuation expectations while retaining a positive outlook on the stock.
3mo agoRBC Capital reiterates Sector Perform on Penumbra, maintains $374 target
RBC Capital analyst Shagun Singh has reiterated a Sector Perform rating on Penumbra, maintaining a price target of $374. The rating affirmation reflects the analyst's current stance on the company's stock performance.
4mo agoPenumbra's THUNDERBOLT gets FDA clearance to treat acute ischemic stroke
Penumbra, Inc. has secured FDA clearance for THUNDERBOLT, the first computer assisted vacuum thrombectomy device designed to treat acute ischemic stroke in the U.S. The technology utilizes modulated aspiration to facilitate faster and more complete clot removal, addressing a critical need as stroke mortality rates are projected to rise globally.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 |
An investment of $100 made 5 years ago in Penumbra is now worth
$ 115.63
giving a profit of
$ 15.63 (15.63%)
Note: Past profits do not guarantee future returns.
